Danielle Roman, PharmD, BCOP
Although typically associated with advanced breast cancer (BC), cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors may be life changing for patients with early-stage disease who face a high risk for recurrence, according to a session at the HOPA Annual Conference 2024, in Tampa, Fla.
But the agents are not without risk. “Because of the known quantity and potential severity of toxicities, oncology pharmacists should be at the forefront of